Form 4: Immix Biopharma CEO Ilya Rachman Acquires Additional Shares

Immix Biopharma's CEO and Chairman, Ilya Rachman, purchased 4,300 shares of common stock at a price of $2.2465 per share on May 14, 2024.

Summary

• On May 14, 2024, Ilya Rachman, the CEO and Chairman of Immix Biopharma, Inc., acquired 4,300 shares of the company's common stock.
• The purchase price was $2.2465 per share.
• Following this transaction, Mr. Rachman directly owns 912,000 shares of Immix Biopharma's common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally seen as a good sign, but the impact is limited as it's a relatively small transaction.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can influence investor sentiment.

Stakeholder Impact

• The stock purchase may have a minor positive impact on shareholder confidence.

Key Dates